Halder Sutapa, Kundu Sayan, Chakraborty Jayati, Chakrabarti Sudipta
Department of Pathology, ESI PGIMSR, Manicktala Kolkata, 54 Bagmari Road, Kolkata, West Bengal, 7000054, India.
J Gastrointest Cancer. 2019 Dec;50(4):848-854. doi: 10.1007/s12029-018-0162-8.
HER2 is an oncoprotein which is overexpressed in several cancers including breast and stomach. Several studies have shown that HER2 is overexpressed in gallbladder cancer and in precancerous lesions. The present study was undertaken to assess pattern and level of expression of HER2 in metaplasia, dysplasia, and different stages of gallbladder carcinoma, which would determine its suitability as a prognostic biomarker in neoplastic transformation of gallbladder epithelium. The study was also aimed at to find the significance of Ki-67 index in these lesions.
One hundred and twenty-eight patients who underwent cholecystectomy comprised the study group. Among them, 108 (84.4%) specimens showing metaplasia, dysplasia, and carcinoma on routine histopathology were considered as cases and 20 (15.6%) specimens of chronic cholecystitis having non-metaplastic mucosa were considered as control. Immunohistochemistry (IHC) was performed for HER2 and Ki-67. For HER2 interpretation ASCO/CAP guideline for breast cancer was followed. Chi-square test was used to find out the significance of HER2 expression in dysplasia/metaplasia/carcinoma. The ANOVA and Tukey-Kramer Multiple Comparisons Test were used for determining the association of Ki-67 with malignant transformation.
Overexpression of HER2 was observed in 48% (n = 12) of adenocarcinomas, 58% (n = 7) of high-grade dysplasia, 47% (n = 8) of low-grade dysplasia, and 74% (n = 25) of intestinal metaplasia. Ki-67 index increases in a non-linear fashion as the precursor lesions progress toward malignancy. In the future, these markers might be used as a prognostic biomarker for gallbladder carcinoma and its precursor lesions and it might become a valid indication for targeted therapies for gallbladder cancer.
HER2是一种癌蛋白,在包括乳腺癌和胃癌在内的多种癌症中过度表达。多项研究表明,HER2在胆囊癌及癌前病变中过度表达。本研究旨在评估HER2在化生、发育异常及不同阶段胆囊癌中的表达模式和水平,这将决定其作为胆囊上皮肿瘤转化预后生物标志物的适用性。该研究还旨在探究Ki-67指数在这些病变中的意义。
128例行胆囊切除术的患者组成研究组。其中,108例(84.4%)在常规组织病理学检查中显示化生、发育异常和癌的标本被视为病例,20例(15.6%)具有非化生黏膜的慢性胆囊炎标本被视为对照。对HER2和Ki-67进行免疫组织化学(IHC)检测。HER2的判读遵循美国临床肿瘤学会/美国病理学家学会(ASCO/CAP)乳腺癌指南。采用卡方检验来确定HER2在发育异常/化生/癌中的表达意义。采用方差分析和Tukey-Kramer多重比较检验来确定Ki-67与恶性转化的关联。
在48%(n = 12)的腺癌、58%(n = 7)的高级别发育异常、47%(n = 8)的低级别发育异常和74%(n = 25)的肠化生中观察到HER2过度表达。随着前驱病变向恶性发展,Ki-67指数呈非线性增加。未来,这些标志物可能用作胆囊癌及其前驱病变的预后生物标志物,并且可能成为胆囊癌靶向治疗的有效指征。